Bayerische Motoren Werke ADR (BMWYY)

Annovis Bio (NYSE: ANVS) announced it will host a live webcast on June 24, 2025, at 4:30 PM EDT, featuring President and CEO Maria Maccecchini, Ph.D. The event will provide updates on the company’s pivotal Phase 3 trial for early Alzheimer’s disease, recent FDA feedback on its Parkinson’s disease program, and other key initiatives. The webcast will include a brief presentation followed by a live Q&A session open to shareholders, patients, and other stakeholders.

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, PC111—a monoclonal antibody targeting the Fas/FasL pathway—holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders. The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer.

When inflammatory bowel disease becomes chronic, it is difficult to treat and comes with the likelihood of various complications, such as the onset of bowel cancer. This disease in its chronic form manifests as Crohn’s disease or ulcerative colitis. These diseases particularly impact young people. Early diagnosis followed by treatment is crucial in these cases.

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled “The Future and Promise of TPI 287,” will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier.

As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against misuse, using its proprietary Aversa technology to set a new standard for transdermal pain and addiction treatments.

Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show , where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook.

A recent study conducted by experts based at University of Nottingham in the UK has revealed that young individuals afflicted by certain kinds of cancer like bone malignancies take longer before being diagnosed .

Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5 at 4 p.m. ET. The session will feature a fireside-style Q&A open to live audience questions, with 1×1 meetings available for qualified investors. A webcast of the presentation will be accessible post-event on Nutriband’s website and Channelchek.com, where it will remain archived for 90 days.

Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch. A newly formalized partnership with Kindeva Drug Delivery will support shared development costs in exchange for milestone payments as AVERSA moves toward regulatory approval. The product is projected to reach peak U.S. sales of $80 million to $200 million annually.

Before embarking on the thrilling EXTREME Russia expedition with QJMOTOR and Benelli, Ksyusha, the adventurous rider, sought expert guidance to ensure a safe and exhilarating journey. She received a meticulous pro briefing from Evgeny Pyatigorsky, the esteemed Chief Instructor of BMW Motorrad Russia and a seasoned expert in the grueling Silk Way Rally. With decades of experience navigating extreme terrains and a reputation for training elite riders, Pyatigorsky’s insights were invaluable in preparing Ksyusha for the challenges ahead.

A recently conducted study by a team at Karolinska Institutet in Sweden has established a link between a diagnosis of autism spectrum disorder (ASD) to a heightened risk of Parkinson’s disease (PD). The research appeared in the journal JAMA Neurology . The research team believes the two conditions may share a number of underlying biological mechanisms.

Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year period, reflecting continued expansion of its CDMO business. R&D expenses declined to $1.3M from $1.6M, while marketing, general and administrative costs held steady at $500K. The company recorded a $1.6M net loss, improving from a $2.2M loss in Q1 2024, aided by reduced R&D and financial expenses. Cash and equivalents totaled $1M at quarter-end, down from $2M a year earlier.

Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory,” the Atlanta-based company is advancing a robust pipeline of therapies aimed at delivering long-overdue innovation in safety, efficacy, and tolerability. Rather than tweaking existing treatments, Alzamend is engineering bold new approaches that directly address the limitations of current standards of care.

Texas’ Cancer Prevention & Research Institute has awarded $3 million to the University of Houston to establish a biomarker core for cancer immunotherapy. The research institute has earned a reputation for funding research projects which are groundbreaking. The $3m is a fraction of its $93m total package earmarked for awarding grants to entities within the state.

Gilston, QLD () May 28, 2025 -- Paradise Car Keys’s specialized services for luxury brands include EEPROM programming, ignition repairs, and advanced diagnostics.

On May 22, the U.S. House of Representatives approved the reconciliation bill for the 2025 budget with a one-vote difference between those in support of the bill and those opposed to it. The American Hospital Association says this legislation is going to have notable impacts upon healthcare insurance and Medicaid.

TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences and other prestigious institutions underscores his impact on the field. TransCode leaders praised the addition as a strategic enhancement to the company’s RNA-targeted cancer therapy programs.

Oragenics (NYSE American: OGEN) announced that its board has approved a 1-for-30 reverse stock split of its common shares, effective June 3, 2025. The move consolidates every 30 shares into one and aims to boost the company’s share price and appeal to long-term investors. Shares will begin trading on a split-adjusted basis under the existing symbol “OGEN” with a new CUSIP number. CEO Janet Huffman stated the action aligns with Oragenics’ strategy to enhance its capital markets profile while advancing treatments for brain-related health conditions.

The GI tract and its components like the mucosal lining play an important role of preventing harmful substances from finding their way into the bloodstream. When this mucosal lining is compromised, serious consequences like the entry of undigested food, toxins and bacteria into the bloodstream result. “Leaky gut” is responsible for conditions like inflammatory bowel disease.

Whop's study reveals one-third of Gen Z consumers regularly make purchases based on AI-generated influencer recommendations, highlighting AI influencers' rising trust and influence among young consumers on social media platforms.

While startup headlines are often dominated by moonshot valuations and flashy funding rounds, there's a consultancy quietly turning raw potential into real money — and doing it with ruthless precision.

In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying on traditional antibiotics.

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S. launch in 2025, as it is progressing through the FDA clearance process for its Intelligent Fingerprinting Drug Screening System. The non-invasive device, which detects recent drug use via fingerprint sweat, is gaining international traction for its speed, portability, and ability to integrate into a range of safety-critical environments.

In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 ( https://ibn.fm/9K5zT ). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including a strong partnership with Kindeva Drug Delivery.

Researchers have developed a novel brain tumor test that surgical experts have dubbed a game changer. This is because the test collapses the needed time to obtain an accurate diagnosis to just hours rather than multiple weeks as has been the case.